-
-
Detecting HIV early creates opportunity for treatment and reduces transmission risk.
-
-
The American College of Physicians recommends against performing screening pelvic examination in asymptomatic, nonpregnant, adult women.
-
The first in a new class of orexin receptor antagonists has been approved by the FDA for the treatment of insomnia. Orexins are hypothalamic neuropeptides that appear to have a role in maintaining wakefulness.
-
-
In a systematic review and meta-analysis of prospective studies examining the association between mental stress-induced myocardial ischemia (MSIMI) and adverse outcome events in patients with stable CAD, all existing investigations point to an approximate doubling of cardiovascular risk in patients with MSIMI.
-
Makani H, et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis.
-
The trouble with the expense of treating hepatitis C virus (HCV) infections is that very few patients are acutely choking on it, since the largest pool of HCV patients are asymptomatic. Progression to end-stage liver disease, liver transplantation, and hepatocellular carcinoma the three most dreaded HCV consequences may seem distant to the asymptomatic or even modestly symptomatic patient.
-
The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik.